Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC reduced its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 35.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 401,526 shares of the biopharmaceutical company’s stock after selling 222,513 shares during the period. Squarepoint Ops LLC owned 0.07% of Royalty Pharma worth $10,588,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Versant Capital Management Inc boosted its holdings in Royalty Pharma by 5,215.0% in the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,043 shares during the last quarter. Gladius Capital Management LP acquired a new position in shares of Royalty Pharma in the 2nd quarter valued at about $32,000. Fidelis Capital Partners LLC acquired a new position in shares of Royalty Pharma in the 1st quarter valued at about $46,000. GAMMA Investing LLC grew its holdings in shares of Royalty Pharma by 172.5% during the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,037 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 655 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $28.21 on Friday. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35. The company’s fifty day moving average price is $28.01 and its two-hundred day moving average price is $27.91. The firm has a market capitalization of $16.74 billion, a P/E ratio of 21.05, a P/E/G ratio of 4.09 and a beta of 0.46. Royalty Pharma plc has a 12 month low of $25.20 and a 12 month high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The business had revenue of $537.00 million for the quarter, compared to analysts’ expectations of $600.83 million. During the same quarter in the previous year, the firm posted $0.85 earnings per share. On average, research analysts anticipate that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Friday, August 16th were paid a $0.21 dividend. The ex-dividend date was Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.98%. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. UBS Group downgraded shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective for the company. in a research note on Monday, June 3rd. Morgan Stanley upped their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Finally, The Goldman Sachs Group upped their target price on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Royalty Pharma has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.